Esperion Therapeutics (ESPR) Is Surging On FDA News

Shutterstock photo

( - Esperion Therapeutics ( ESPR ) announced Monday morning that the FDA has confirmed that the company's LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid.

Esperion Therapeutics has gapped open sharply higher this morning and is now up 10.33 at $34.00 on above average volume. The stock has jumped to a 1-week high and is challenging the highs of the year.

For comments and feedback: contact

This article appears in: Stocks , Stocks
Referenced Symbols: ESPR

More from RTT News


See headlines for ESPR

Follow on: